Early-Stage Funding Gap Targeted By Two New U.K. Funds, Deepbridge Innovation Fund And Target Development Fund
This article was originally published in The Pink Sheet Daily
Executive Summary
Deepbridge Capital aims to raise £250 million to support early-stage research, recruits ex-GSK CEO Sykes to chair investment committee.
You may also be interested in...
U.K Tech Transfer Firm IP Group Raises $90 million To Support Early-Stage Portfolio Companies
IP Group raises funds to support academic spin-outs as VC funds and IPOs remain scarce
Imperial Innovations Raises £140 Million To Invest In University Spin-Outs
The AIM-listed tech transfer group will increase its early-stage investments in spin-outs from Imperial College and three other top UK universities
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.